Boston Scientific (NYSE:BSX) has received diverse analyst ratings over the last three months, with a total of 10 analysts offering perspectives ranging from bullish to bearish. The recent ratings show an increase in bullish sentiment, with an average 12-month price target set at $64.9, marking a 7.97% increase from the previous average of $60.11. Analysts from firms like Needham, RBC Capital, and Raymond James have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Boston Scientific is known for producing less invasive medical devices, with foreign sales making up nearly half of its total sales. Despite its strong market position and revenue growth, the company faces challenges in ROE and ROA, indicating potential difficulties in efficiently utilizing equity capital and assets.